Clinical Scorecard: The Role of Immunothrombosis in the Immune Response and Pathogenesis of Mycobacterium tuberculosis
At a Glance
Category
Detail
Condition
Tuberculosis (TB) caused by Mycobacterium tuberculosis
Key Mechanisms
Immunothrombosis involving macrophages, neutrophils, platelets, tissue factor, and NETs leading to microthrombosis at infection sites
Target Population
Patients with active tuberculosis, including those with multidrug-resistant TB and comorbidities such as HIV and diabetes
Care Setting
Infectious disease and pulmonary care settings, including hospital and outpatient management of TB
Key Highlights
Immunothrombosis traps Mycobacterium tuberculosis locally to prevent dissemination but dysregulation can cause tissue damage and drug resistance.
Elevated coagulation markers (D-dimer, fibrinogen, von Willebrand factor) and endothelial dysfunction are common in TB and contribute to disease severity.
Tissue factor expression by macrophages is critical for granuloma formation and controlling Mtb growth, implicating coagulation pathways in TB pathogenesis.
Guideline-Based Recommendations
Diagnosis
Consider screening for venous thromboembolism in TB patients, especially those with severe illness or comorbidities such as HIV or diabetes.
Monitor coagulation markers (D-dimer, fibrinogen, vWF) to assess coagulation activation and endothelial dysfunction in TB.
Management
Further research is needed to develop host-directed therapies targeting immunothrombosis to reduce lung damage and drug resistance.
Manage TB with standard antimycobacterial therapy while considering the potential impact of immunothrombosis on drug delivery and resistance.
Monitoring & Follow-up
Monitor for signs of thromboembolism and coagulopathy during TB treatment.
Assess lung function and fibrosis progression post-TB to evaluate long-term effects of immunothrombosis.
Risks
Dysregulated immunothrombosis may increase risk of lung tissue destruction, venous thromboembolism, and contribute to multidrug resistance.
Comorbid conditions such as HIV and diabetes increase risk of coagulation abnormalities and worse TB outcomes.
Patient & Prescribing Data
Patients with active tuberculosis, including those with multidrug-resistant strains and comorbidities
Standard antimycobacterial regimens remain primary treatment; however, immunothrombosis may impair drug delivery and contribute to resistance, highlighting the need for adjunct host-directed therapies.
Clinical Best Practices
Recognize immunothrombosis as a component of the innate immune response in TB that can become pathogenic if dysregulated.
Screen and monitor TB patients for coagulation abnormalities and thromboembolic events, especially in high-risk groups.
Support research into host-directed therapies targeting immunothrombosis to improve TB outcomes and reduce lung damage.
